Zydus Cadila gets DCGI nod for launch of its NCE for diabetes
New Delhi: Cadila Healthcare today said Indian drug regulator has approved its new chemical entity, Lipaglyn to be used for treating a type of diabetes for launch in the country.
Drug Controller General of India (DCGI) has approved Lipaglyn to be used for treating `diabetic dyslipidemeia` for launch, the company said in a filing to BSE.
Commenting on the development Zydus Cadila Chairman and Manging Director Pankaj R Patel said: "Lipaglyn provides patients suffering from diabetic dyslipidemia the option for once-daily oral therapy that has a beneficial effect on both lipid parameters as well as glycemic control."
It has always been our dream to take a molecule right from concept stage to its launch. Today we have realised this dream, he added.
Diabetic dyslipidemeia is a condition where a person is diabetic and has elevated levels of total cholesterol.
Shares of Cadila healthcare were today trading at Rs 780.85 per scrip in the afternoon trade on BSE, down 4.13 per cent from its previous close.
More from India
More from World
More from Sports
More from Entertaiment
- Indrani 'slow-poisoned' Sheena, wanted to portray Mikhail as 'mentally unstable'?
- 'Mann ki Baat': Will implement 13 new pointers to Land Bill from today itself, says PM Modi
- Will not allow any political party to join agitation: Hardik Patel
- People have no faith left in Modi government: Sonia Gandhi at Swabhiman rally
- Lashkar-e-Toiba plotting 26/11-style attack in India with the help of Pak Navy, ISI?
- Satire website publishes article on Osama bin Laden being alive and quotes Edward Snowden
- Indrani's former brother-in-law claims Sheena was Siddharth Das' daughter
- Sheena Bora murder case: 'Indrani Mukerjea's father thrashed her with belt'
- Sheena murder: Suitcase seized from Indrani, Peter's residence meant for disposing Mikhail's body?
- Amitabh Bachchan's Twitter account hacked, sex sites planted as 'following'